Tzivelekis S, Orange J, Poulos C, Meckley LM, Peay H, Sutphin J, Hernandez-Trujillo VP, Wasserman RL. Development of a novel shared decision making aid for primary immunodeficiency diseases. Immunotherapy. 2023 Jun;15(9):647-56. doi: 10.2217/imt-2022-0193
Crowe HM, Wesselink AK, Wise LA, Jick SS, Rothman KJ, Mikkelsen EM, Sorensen HT, Hatch EE. Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study. J. Headache Pain. 2022 Dec 20;23(1):162. doi: 10.1186/s10194-022-01533-6
Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naïve patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022 Apr;14(5):373-87. doi: 10.2217/imt-2021-0265
Yuguero O, Marsal JR, Buti M, Esquerda M, Soler-Gonzalez J. Descriptive study of association between quality of care and empathy and burnout in primary care. BMC Med Ethics. 2017 Sep 26;18(1):54. doi: 10.1186/s12910-017-0214-9
Matharu M, Pascual J, Nilsson Remahl I, Odom D, Gutierrez L, Andrews E, Largent J, Johannes C. EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union. Poster presented at the 4th European Headache and Migraine Trust International Congress 2014; September 2014. Copenhagen, Denmark. [abstract] J. Headache Pain. 2014 Sep 18; 15(Suppl 1):G24. doi: 10.1186/1129-2377-15-S1-G24
Brubaker L, Richter HE, Barber MD, Hsu Y, Rahn DD, Menefee S, Visco A, Spino C, Martin S, Meikle SF. Pelvic floor disorders clinical trials: participant recruitment and retention. Int Urogynecol J. 2013 Jan 1;24(1):73-9.